73 results about "Chronic myeloid leukaemia" patented technology

Methods are provided for treating patients with hematological disorders such as acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and the myelodysplastic syndromes (MDS). By administering a DNA methylation inhibitor to the patients following unique dosing regimens, the diseases can be efficaciously treated with reduced toxic side effects.

The invention provides an electrochemical DNA biosensor for detecting the BCR/ABL fusion gene of chronic myeloid leukemia (CML), which comprises the following steps of: (1) designing and synthesizing the specificity sequence of the CML according to the fusion locus of the universal primer sequence of the selected CML gene type to be detected; and (2) building the electrochemical DNA biosensor by combining a chemical bonding technology, a molecular hybridization technology, a locked nucleic acid probe technology with an electrochemical enzyme linked immunity technology for detecting the BCR/ABL fusion gene of the CML. The biosensor greatly strengthens the sensitivity and the specificity, thereby being capable of realizing the early diagnosis of the chronic myeloid leukemia (CML).

The invention discloses a pharmaceutical composition for treating acute or chronic myeloblastic leukemia, which is characterized in that: it is made of dehydrated galactitol, kudzuvine root and pharmaceutical auxiliary materials. The composition in the invention has evident effect for treating leukemia, has an undoubted effect for treating lung cancer, multiple myeloma and nasopharyngeal carcinoma, especially has a preferable near term effect for treating chronic myeloblastic leukemia with a remission rate of 86%, has a higher effect for treating various lung cancer, and has lower poisonous and side effects.

The invention relates to a system for enabling the cell apoptosis of chronic myeloid leukaemia. The system is formed by connecting two fusion peptides N3R of an adenovirus vector, two compounds AP21967 and fusion peptide F2S of the adenovirus vector together. Through experimental verification, the system can be used for achieving and realizing induction of CML (Chronic Myeloid Leukemia) cell apoptosis, is good in effect, and has great research values on researching the treatment of leukaemia and developing medicaments.

Immunotherapy utilizing naked anti-granulocyte antibodies provides an effective means for treating chronic myelocytic leukemia (CML). Such antibodies can be administered alone or in combination with other therapies, such as immunoconjugates or chemotherapeutics. In either format, an effective therapy for treating CML is provided, which avoids the toxic side-effects typically associated with cancer therapy. The disclosed immunotherapy also is effective for treating acute myelocytic leukemia (AML) when co-administered with inducing agents which induce expression of antigens minimally displayed on the surface of myeloblasts.

New polymorphs of 5-amino or substituted amino 1,2,3-triazole and substituted derivatives thereof, of orotates of the carboxyamidotriazoles, of formulations of the triazoles and orotic acid in the ratio of 1:1 to 1:4 (base:acid) and of safer processes of the preparation of the same are disclosed. The compounds are useful in the control and treatment of diseases including, but not limited to solid cancers, macular degeneration, retinopathy, chronic myeloid leukemia, AIDS and diseases which rely on aberrant signal transduction. The improved processes to prepare the orotate formulations use stable, efficient and safer starting azide intermediate materials in the synthesis of new polymorphs of carboxyamidotriazole.

The invention relates to a traditional Chinese medicine preparation for treating chronic granulocytic leukemia, comprising the following raw materials according to parts by weight: 28 to 32 parts of indigo naturalis, 14 to 16 parts of realgar, 14 to 16 parts of mastic, 0.28 to 0.32 part of musk and 14 to 16 parts of myrrh. The traditional Chinese medicine preparation has the characteristics of good curative effect, low toxicity and low price.

Inhibitors of casein kinase 2 are described that have been found to arrest uncontrolled cell proliferation, thereby suggesting their use in cancer treatment strategies. Specific applications include treating breast cancer, colon cancer, melanoma, chronic myelogenous leukemia, bladder cancer, renal cancer, and brain cancer. Various methods and compositions utilizing the inhibitors are described.

The present invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, said composition comprising an effective amount of analogs of chlorogenic acid such as neochlorogenic acid (5-O-caffeoyl quinic acid), cryptochlorogenic acid (4-O-Caffeoyl quinic acid), 3-O-(3'-methylcaffeoyl) quinic acid and 5-O-(Caffeoyl-4'-methyl) quinic acid and/or its salts such as sodium, potassium and ammonium together with pharmaceutically acceptable additives.

The invention discloses cryptotanshinone pharmaceutical composition and an application thereof in preparation of a CML (chronic myeloid leukemia) treatment drug. The cryptotanshinone pharmaceutical composition contains cryptotanshinone and a tyrosine kinase inhibitor, with the adoption of cryptotanshinone for treatment, protein expression level of Bcr-Abl genes in CML K562 and multi-drug resistantstrains K562/ADM cells can be remarkably reduced, cell proliferation inhibition ratio of the tyrosine kinase inhibitor is increased, and apoptosis rate of CML K562 cells and K562/ADM cells can be remarkably increased through combination of cryptotanshinone and the tyrosine kinase inhibitor. With the adoption of the cryptotanshinone pharmaceutical composition, chemosensitivity of tyrosine kinase can be improved, chemotherapy drug dosage of a patient is reduced, toxic and side effects on a human body are reduced, and a new treatment scheme is provided for clinical treatment of CML.

The invention belongs to the field of biological medicine, and particularly relates to application of berberine in preparing a drug for overcoming the drug resistance of chronic granulocytic leukemia or a drug sensitizer for resisting chronic granulocytic leukemia. Berberine can improve the sensitivity of chronic granulocytic leukemia cells to imatinib and overcome the multi-drug resistance of chronic granulocytic leukemia cells to imatinib. Berberine degrades BCR-ABL protein mainly through a ubiquitination mechanism, and thus the multi-drug resistance of chronic granulocytic leukemia caused by T315I mutation is overcome.

The invention relates to a Chinese medicinal composition for treating chronic myeloid leukemia, which consists of the following components: 15 to 25 grams of rehmanniae praeparatum, 8 to 16 grams of tree peony bark, 18 to 28 grams of honey-fried extract glycyrrhiza, 18 to 32 grams of spreading hedyotis herb, 14 to 20 grams of lalang grass rhizome, 18 to 28 grams of glossy privet fruit, 14 to 28 grams of desertliving cistanche, 4 to 8 grams of cordyceps sinensis, 12 to 20 grams of Indian iphigenia bulb, 8 to 16 grams of stiff silkworm and 8 to 16 grams of eupolyphaga. The Chinese medicinal composition can carry out pertinence treatment on chronic myeloid leukemia, selectively inhibits and kills immature cells, induces apoptosis of leukemia cells, has strong pertinence and better treatment effect, promotes differentiation and maturation of leukemia cells, regulates qi and blood, strengthens the immunity, promotes recovery of the normal hematopoietic function of bone marrow, reduces reversion, prevents tolerance from being generated, reduces the toxic or side effects of chemotherapy and strengthens physical fitness.

The invention discloses a kit capable of detecting expression quantity of BAALC (brain and acute leukemia cytoplasmic) gene mRNA (Messenger Ribose Nucleic Acid), belonging to the field of biotechnology. The kit comprises a detection primer and fluorescence probe, a cDNA first strand synthesis reagent, fluorogenic quantitative PCR (Polymerase Chain Reaction) mixed liquor, negative control and positive control, wherein the primers and fluorescence probes for detection include a BAALC gene primer, a reference gene ABL primer and a Taqman fluorescence probe. The BAALC gene is a sign of progenitor cell of early hematopoietic cell, and is abnormally expressed in acute and chronic patients with AML (Acute Myelocytic Leukemia), ALL (Acute Lymphocytic Leukemia) and CML (Chronic Myeloid Leukemia). According to the embodiment of the invention, the mRNA level of the BAALC gene is detected by fluorogenic quantitative PCR with high sensitivity and specificity, and the specificity and sensitivity of the detection result are both obviously improved. The kit can provide a brandnew, fast, simple and convenient gene diagnosis technology for clinically evaluating the diagnosis, prognosis and reappearance period of acute lymphocytic leukemia.

The invention provides a novel molecular target HES6 for treating chronic myeloid leukemia (CML), correspondingly provides a HES6-based early diagnosis kit for treating the chronic myeloid leukemia, and further provides a method for promoting K562 cell differentiation through HES6 overexpression.

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

The invention disclosed herein is directed to compounds of Formula (1a) and (1b) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocyticδ leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (1a) or (1b), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a compound which is a dual antagonist of PPARα and PPARδ. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a herapeutically effective amount of a dual antagonist of PPARα and PPARδ.

The present invention relates to the diagnosis of hematopoietic disorders and to determining the prognosis of patients affected by such disorders. The methods generally comprise determining a level of myeloperoxidase in a body fluid sample from the individual and using the level as a factor for diagnosing the disorder in the mammal or as a factor for determining the prognosis of a patient diagnosed with such a disorder. Myelodysplastic syndrome, acute myeloid leukemia and chronic myeloid leukemia are exemplary disorders. Also provided are method of cancer therapy involving reducing the level of myeloperoxidase in the body fluid of the individual.

The invention discloses application of Cephaloziellin F in preparation of drugs for treating chronic granulocytic leukemia, and belongs to the field of drugs. According to research, the Cephaloziellin F can directly inhibit proliferation of K562 cells, and inhibiting ability is improved along with increasing of concentration and extension of action time. Moreover, the Cephaloziellin F can induce K562 cell apoptosis, and the apoptosis promoting effect can be improved along with increasing of the concentration and extension of the time. Therefore, the Cephaloziellin F can be further researched and developed into the drugs for treating the chronic granulocytic leukemia.

The invention belongs to the technical field of medical biology, and particularly relates to application of umbilical cord-derived mesenchymal stem cells combined with TPO and analogues thereof in preparation of drugs for treating chronic myelogenous leukemia. The mesenchymal stem cells are human-derived umbilical cord mesenchymal stem cells (UC-MSCs), can efficiently induce differentiation of chronic myeloid leukemia cells after being combined with a TPO analogue Eltrombopag, and the capability is realized by secreting TPO by MSCs and inducing leukemia cells to express a TPO receptor (MPL); and compared with chemotherapy, mesenchymal stem cell transplantation is lower in toxic and side effects, has low immunogenicity and meets clinical requirements, and the Eltrombopag is a clinically approved drug. The method provides a new thought for stem cell transplantation treatment of myeloid leukemia, and can be applied to differentiation treatment of myeloid leukemia.

As disclosed herein, the invention relates to a method of screening for a therapeutic for chronic myeloid leukemia. In an aspect, the invention relates to transgenic Drosophila. In an aspect, the invention relates to a Drosophila system for screening compounds treating chronic myeloid leukemia.

The invention discloses a chronic myeloid leukemia DNA vaccine BCR/ABL-pIRES-SEA and a preparation method and an application thereof, the DNA vaccine contains a pIRES plasmid, a BCR/ABL gene and an SEA gene, wherein, the BCR/ABL gene and the SEA gene are respectively positioned on multi-clone sites at two sides of an IRES element on the pIRES plasmid; nucleotide sequences of the BCR/ABL gene and the SEA gene are shown in SEQ ID No.1 and SEQ ID No.2; the DNA vaccine can express BCR/ABL protein and SEA protein; the DNA vaccine can express BCR/ABL protein and SEA protein in eukaryocyte; when being injected into mice, the DNA vaccine can stimulate organism to generate specificity CD8+T cells aiming at CML cells, accompanying increased secretion of a cell factor, thus eradicating minimal residual disease in the bodies of patients, therefore the invention can be applied to prepare drugs for treating chronic myeloid leukemia.

The invention discloses a plant medicine used to cure chronic myeloid leukemia. The medicine takes stellera chamaejasme, one of the daphne plants as the main ingredients. The medicine is made by soaking the stellera chamaejasme in milk. The invention fills up the blank of medicines which can be used to cure chronic myeloid leukemia effectively; after patients with chronic myeloid leukemia use the medicine, chronic myeloid cells in the blood of the patients decrease significantly and even disappear; the invention has good clinical results.